1.What is Semaglutide?
Semaglutide is a medication used for the treatment of type 2 diabetes and for long-term weight management in individuals with obesity or excess weight.
It is a peptide drug known as glucagon-like peptide-1(GLP-1) receptor agonists and designed to mimic the action of GLP-1 hormone, which is released in the gut after eating.
Semaglutide works by helping the pancreas release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar in the blood to other body tissues where it is used for energy. Ọgwụ Semaglutide na-ebelatakwa mmegharị nke nri site na afọ, nke nwere ike ibelata agụụ ma bute ibu ibu.
Atọ bụ ụdị atọ nke Semaglutide maka ọrịre n'ahịa ugbu a, Ozempic, Wegovy na Rybelsus.
2.What’s the mechanism of Semaglutide peptide?
Dị ka glucagon-dị ka peptide-1(GLP-1) agonist anabata, Semaglutide na-arụ ọrụ ya iji belata ọkwa shuga dị n'ọbara site na ijikọ ndị na-anabata GLP-1 na mkpụrụ ndụ beta pancreatic iji kpalite insulin secretion ma belata ntọhapụ nke glucagon., na-enyere aka ị nweta glucose.
Na mgbakwunye, ọgwụ ahụ na-ebelata mkpofu afọ, na-akwalite satiety ogologo oge na nnabata nri a na-achịkwa. Nke a na-eme ka afọ ojuju dị elu ma belata agụụ, na-akwalite mmekọrịta nke semaglutide na ndị na-anabata GLP-1 na ụbụrụ.
Usoro ndị a na-ejikọta ọnụ na-eme ka njikwa shuga dị n'ọbara ka mma, belatara agụụ na ọnwụ na-adịgide adịgide, na-eme ka ndị mmadụ na-azụta Semaglutide maka njikwa ọrịa shuga na njikwa ibu ogologo oge.[1]
3.What are the benefits of Semaglutide?
Ka ọchịchọ na mmasị na Semaglutide peptide na-eto, otú ahụ ka nnyocha e mere na ya si dị. Ọ bụghị naanị Semaglutide na-enye ọtụtụ uru maka ndị nwere ụdị 2 ọrịa shuga na ndị na-achọ ịchịkwa ibu ha, ọ nwekwara mmetụta nwere ike na ọgwụgwọ nke ọrịa imeju na-ebu abụba na nsogbu ụbụrụ uche. Uru akọwapụtara nwere ike ịdịgasị iche dabere na ọnọdụ a na-agwọ ya. Nke a bụ uru bụ isi nke iji Semaglutide ntụ ntụ:
Semaglutide ogwu ogbugba maka Ụdị 2 Ọgwụgwọ ọrịa shuga mellitus: A kwadoro Semaglutide ugbu a dị ka ụdị 2 ọrịa shuga mellitus (T2D) ọgwụgwọ. Mgbe ntụtụ nke Semaglutide, Ihe na-arụ ọrụ nke Semaglutide na-eṅomi hormone GLP-1 mmadụ. Na-enyere aka ịhazi ọkwa shuga dị n'ọbara site na ịba ụba mmepụta insulin na ibelata mmepụta glucagon. This allows for better blood sugar control and reduces the risk of high blood sugar. N'otu oge, Semaglutide has been shown to reduce HbA1c levels, which is a marker of average blood sugar levels over time. Lowering HbA1c reduces the risk of diabetes-related complications. Semaglutide has demonstrated a relatively low risk of hypoglycemic events compared with other antidiabetic drugs.
Semaglutide ogwu ogbugba for Weight Loss: Semaglutide is also approved as a weight management treatment. Study Shows Semaglutide Effective as Weight Loss Drug in Both Diabetic and Non-Diabetic People. Dị ka nchọpụta si kwuo, after injection of Semaglutide, it will increase satiety and suppress appetite to achieve anti-obesity effect. According to one 68-week study, adults who injected Semaglutide lost an average of 35 pounds, ma ọ bụ 15 percent of their total body weight. If you have been battling obesity or are overweight and have not been successful with lifestyle changes alone, Semaglutide may provide the extra support you need. Plus, you’ll get great prices on buying Semaglutide powder in bulk.
Semaglutide ogwu ogbugba for Cardiovascular Risk: As a hot sale weight-loss drug on the market, the breakthrough of Semaglutide lies not only in the weight-loss effect itself, but also in its ability to indirectly regulate body weight and directly act on the cardiovascular system. It can show comprehensive cardiovascular health benefits for obese people and T2DM people .
Research shows that Semaglutide has significant effects of lowering blood sugar, promoting weight loss, lowering blood pressure, and lowering blood fat. These effects indirectly contribute to cardiovascular protection. Obesity is an important factor in the development of various health problems, including abnormal blood lipid levels, ụdị 2 diabetes mellitus (T2DM), high blood pressure and obstructive sleep apnea. These conditions increase the likelihood of cardiovascular disease, which remains the leading cause of death worldwide. Ya mere, it is crucial to address overweight in overweight or obese individuals to prevent cardiovascular disease
Other Potential Benefits of Semaglutide ogwu ogbugba: As people’s research on Semaglutide continues to deepen, the benefits of Semaglutide are also emerging in front of people. In addition to effectively treating diabetes and weight management, Semaglutide also shows great potential in treating or preventing cognitive decline and dementia, treating cancer and fatty liver, and anti-inflammation.
❶Semaglutide maka Cognitive Decline and Dementia: The impact of obesity in midlife on dementia in later life has been proven. Research shows that people who are overweight or obese have a higher risk of developing dementia in the future, and that treating obesity early in life can help reduce dementia risk. In addition to its approved use for weight loss and hypoglycemia, Semaglutide also shows promise in the fields of anticancer and neurodegeneration. It has attracted attention for its potential in alleviating neurodegenerative diseases. GLP-1 is a natural hormone that regulates blood sugar and a neurotransmitter whose receptors are expressed in various regions of the brain.Studies have shown a significant reduction in the incidence of dementia in individuals taking GLP-1 receptor agonists.
❷Semaglutide for Cancer: A study recently published in the journal Obesity shows that these long-acting glucagon-like peptide-1 (GLP-1) receptor agonist can reverse the impaired function of natural killer cells (NK cells) in obese patients, which This change was not caused by weight loss.
Researchers at Maynooth University in Ireland carried out the study involving 20 obese patients. They found that the GLP-1 analog restored the function of natural killer cells, the white blood cells responsible for fighting viruses and cancer cells. Other studies have shown that GLP-1 regulates macrophages, natural killer cells and T cells.
GLP-1 treatment directly improves NK cell cytokine production and metabolic activity, potentially providing the broader advantages of this class of drugs in obese patients.
❸Semaglutide for fatty liver: Ọrịa imeju abụba na-adịghị egbu egbu (NAFLD) bụ ọrịa na-aga n'ihu nke na-egosi na mbụ dị ka steatosis dị mfe (ọrịa imeju abụba na-abụghị mmanya ma ọ bụ NAFL). Oge n'aga, ọ nwere ike ịmalite ịghọ ụdị mgbagwoju anya nke a na-akpọ steatohepatitis na-adịghị egbu egbu (NASH), nke a na-akpọ steatosis, mbufụt na fibrosis. Ọ bụrụ na a naghị agwọ ya, NASH nwere ike ịga n'ihu na cirrhosis na, n'ọnọdụ ụfọdụ, hepatocellular carcinoma (HCC).
Nnyocha egosiwo na GLP-1RA (glucagon-dị ka peptide-1 agonist nnabata) dị irè n'ibelata ọkwa transaminase na abụba imeju na ndị ọrịa nwere T2DM na NAFLD. Semaglutide bụ ọgbọ ọhụrụ nke GLP-1RA, nke nwere ike ọ bụghị naanị ibelata shuga ọbara ma kwalite ibu ibu, ma na-emeziwanye ihe ize ndụ nke obi dị iche iche. Na mgbakwunye, ọmụmụ egosila na GLP-1RA nwere ike ibelata abụba imeju na ndị ọrịa nwere ụdị 2 ọrịa shuga mellitus, na-atụ aro ike ya iji melite ọnọdụ imeju abụba abụba.
GLP-1RA na-egosi nkwa na ọgwụgwọ NAFLD. Maka ndị ọrịa nwere ma T2DM na NAFLD, ọkachasị ndị buru oke ibu ma ọ bụ buru oke ibu, Enwere ike ịtụle mmalite nke ọgwụgwọ semaglutide. Semaglutide abụghị naanị na-enyere aka ịchịkwa shuga ọbara ma kwalite mbelata ibu, ma na-emekwa ka abụba abụba na imeju metabolism dịkwuo mma, si otú ahụ na-akwalite ọrụ imeju, nnabata ndidi, nnabata ọgwụgwọ na ịdị mma nke ndụ.
❹Semaglutide maka mbufụt: Mbufụt bụ nzaghachi dị mkpa maka ihe ịma aka dị ka ọrịa na nrụzi anụ ahụ. Agbanyeghị, Ejikọtala mbufụt na-adịghị ala ala na ọrịa ndị dị ka ụdị 2 ọrịa shuga mellitus, metabolic syndrome, oke ibu, ọrịa kansa, na ndị ọzọ. Nnyocha e mere n'oge na-adịbeghị anya egosila na GLP-1 na analogs ya nwere ike belata nzaghachi mkpali na ụdị anụmanụ.
Ekwesiri iburu n'uche na mmetụta nke Semaglutide na-abawanye mgbe ejikọtara ya na nri na-edozi ahụ., emega ahụ mgbe niile, na nlekọta ahụike na-aga n'ihu. Dị ka ọgwụ ọ bụla, Ekwesịrị inyocha ihe ọjọọ na mmeghachi omume nke onwe onye ọkachamara ahụike.[2]
4.What are the side effects of Semaglutide injections?
Ọtụtụ mmetụta Semaglutide dị nro ma na-adịte aka mgbe onye ọkachamara ahụike nyere ya ndụmọdụ ma na-elekọta ya.
Mgbe a na-agbanye Semaglutide, ọzịza/ọbara ọbara/itching na saịtị ịgba ahụ, ike ọgwụgwụ, ọgbụgbọ, vomiting, afọ ọsịsa, ma ọ bụ afọ ntachi nwere ike ime. Ọgbụgbọ na-ebelata ka ị na-aga n'ihu na-eji Semaglutide. Ọ bụrụ na mmetụta ndị a na-adịgide ma ọ bụ na-akawanye njọ, gwa dọkịta gị okwu ozugbo.
Ọ bụ ezie na Semaglutide anaghị akpata hypoglycemia, enwere ihe ize ndụ nke hypoglycemia mgbe ejiri ya na ụfọdụ ọgwụ ọrịa shuga.
A na-adụ ndị ọrịa dị ime na ndị na-enye nwa ara ọdụ ka ha ghara iji Semaglutide.
5.Where to buy Semaglutide powder/injection online?
Enwere ike zụta Semaglutide site na ndenye ọgwụ dị ka ọgwụ mgbochi ọrịa shuga na ọgwụ oke ibu, na e nwere ọtụtụ isi mmalite nke semaglutide ntụ ntụ / injection na ahịa online. Ọ bụrụ na ịchọrọ ịzụta semaglutide raw ntụ ntụ ma ọ bụ semaglutide ntụ ntụ akpọnwụrụ, MOL Changes.ltd bụ ezigbo ebe. Dị ka onye na-emepụta peptide, anyị nwere ụlọ ọrụ nke anyị na R&D etiti. Peptides anyị dabara nke ọma na ọkọlọtọ GMP na ọkwa ọgwụ.
Onye dere edemede a:
Dr. Jean Zeng gụsịrị akwụkwọ na King's college london ngalaba nke Life Sciences & Ọgwụ.
Akwụkwọ Sayensị Sayensị ode akwụkwọ:
Onye edemede kwekọrọ. Adreesị: Ahụike imeju nke Arizona, 2201 W Fairview St #9, Chandler, THE, 85224, USA; Tel.: +1 480 470 4000.
Ngalaba Endocrinology, JSS Academy of Higher Education and Research, Mysore, India
N'ụzọ ọ bụla dọkịta / ọkà mmụta sayensị anaghị akwado ma ọ bụ kwado ịzụrụ ya, ire ere, ma ọ bụ iji ngwaahịa a maka ihe ọ bụla. MOL Changes.ltd enweghị njikọ ma ọ bụ mmekọrịta, pụtara ma ọ bụ ọzọ, ya na dibia bekee. Ebumnuche nke ịkpọ dọkịta a bụ ịnakwere, kwenye na ịja mma nyocha na ọrụ mmepe nke ndị ọkà mmụta sayensị na-arụ ọrụ na peptide a na-agwụ ike.
Ntụtu aka
[1]Naim Alkhouri Safety na arụmọrụ nke ngwakọta ọgwụgwọ yana semaglutide, cilofexor na firsocostat n'ime ndị ọrịa nwere steatohepatitis anaghị egbu egbu: Nke enweghị usoro, Oghere akara ngosi nke II nnwale [akpọpụtara]
[2]Lakshmi Nagendra, Harish BG, Meha Sharma, Deep Dutta Semaglutide na ọrịa kansa: Nyochaa usoro na meta-analysis[akpọpụtara]
